SeaCrest Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

SeaCrest Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,364	Closed	-$229K	–	620
2024 Q1	$229K	Buy	+3,364	New	+$241K	0.03%	533
2022 Q3	–	Sell	-1,224	Closed	-$74K	–	808
2022 Q2	$74K	Buy	+1,224	New	+$72K	0.01%	963
2021 Q4	–	Sell	-9,218	Closed	-$1.03M	–	711
2021 Q3	$1.03M	Buy	9,218 +7,764	+534%	+$975K	0.12%	178
2021 Q2	$235K	Sell	1,454 -255	-15%	-$31K	0.03%	583
2021 Q1	$208K	Sell	1,709 -2,013	-54%	-$304K	0.03%	599
2020 Q4	$570K	Buy	3,722 +353	+10%	+$41.7K	0.08%	260
2020 Q3	$282K	Sell	3,369 -5,544	-62%	-$492K	0.05%	414
2020 Q2	$655K	Buy	+8,913	New	+$521K	0.11%	208
2019 Q2	–	Sell	-757	Closed	-$27K	–	785
2019 Q1	$27K	Buy	757 +69	+10%	+$2.39K	﹤0.01%	1153
2018 Q4	$20K	Sell	688 -240	-26%	-$8.34K	﹤0.01%	1230
2018 Q3	$41K	Sell	928 -1,798	-66%	-$94.2K	0.01%	1079
2018 Q2	$160K	Buy	2,726 +1,826	+203%	+$104K	0.03%	569
2018 Q1	$41K	Buy	+900	New	+$37.1K	0.01%	1035

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

SeaCrest Wealth Management's CRSP Position: Q2 2024 in Review

SeaCrest Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 3,364 shares — an estimated $229K sold.

SeaCrest Wealth Management first reported a position in CRSP in Q1 2018 and held it in 13 quarters. The position peaked at $1.03M in Q3 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

SeaCrest Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
SeaCrest Wealth Management sold 3,364 CRISPR Therapeutics shares in Q2 2024, an estimated $229K.
SeaCrest Wealth Management first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 13 quarters.
SeaCrest Wealth Management's CRISPR Therapeutics position peaked at $1.03M in Q3 2021.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on SeaCrest Wealth Management's 13F filing for Q2 2024, filed 22 Jul 2024.